KR102642293B1 - Composition for preventing or treating skin diseases comprising wikstroemia ganpi - Google Patents
Composition for preventing or treating skin diseases comprising wikstroemia ganpi Download PDFInfo
- Publication number
- KR102642293B1 KR102642293B1 KR1020210104511A KR20210104511A KR102642293B1 KR 102642293 B1 KR102642293 B1 KR 102642293B1 KR 1020210104511 A KR1020210104511 A KR 1020210104511A KR 20210104511 A KR20210104511 A KR 20210104511A KR 102642293 B1 KR102642293 B1 KR 102642293B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- preventing
- ganpi
- wikstroemia
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 241001263989 Wikstroemia Species 0.000 title claims abstract description 17
- 208000017520 skin disease Diseases 0.000 title abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 50
- 239000002537 cosmetic Substances 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 21
- 235000013376 functional food Nutrition 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 120
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 19
- 201000008937 atopic dermatitis Diseases 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 210000003630 histaminocyte Anatomy 0.000 claims description 8
- 230000003796 beauty Effects 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 5
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 229930014626 natural product Natural products 0.000 abstract description 5
- 230000003266 anti-allergic effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 29
- 102000004388 Interleukin-4 Human genes 0.000 description 20
- 108090000978 Interleukin-4 Proteins 0.000 description 20
- 229940028885 interleukin-4 Drugs 0.000 description 20
- 238000009472 formulation Methods 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000007654 immersion Methods 0.000 description 11
- -1 olive oil Chemical compound 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 8
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000008591 skin barrier function Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 241000219000 Populus Species 0.000 description 5
- 210000004241 Th2 cell Anatomy 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 5
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000036572 transepidermal water loss Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 241001481833 Coryphaena hippurus Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- ISAVYTVYFVQUDY-UHFFFAOYSA-N 4-tert-Octylphenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 ISAVYTVYFVQUDY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000202296 Delphinium Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) 추출물을 포함하는 피부질환 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 상기 추출물을 유효성분으로 함유하는, 피부질환 예방 또는 치료용 약학 조성물, 화장료 조성물, 의약외품 조성물 및 건강기능식품 조성물을 제공한다.
상기 조성물은 우수한 항염증 및 항알레르기 활성을 가지며, 천연물을 이용함으로써 독성 및 부작용으로부터 안전하다.The present invention is a tree ( Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) relates to a composition for preventing or treating skin diseases containing the extract, and more specifically, to a pharmaceutical composition for preventing or treating skin diseases, a cosmetic composition, containing the extract as an active ingredient, Provides quasi-drug compositions and health functional food compositions.
The composition has excellent anti-inflammatory and anti-allergic activities, and is safe from toxicity and side effects by using natural products.
Description
본 발명은 거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) 추출물을 포함하는 피부질환 예방 또는 치료용 조성물에 관한 것이다.The present invention is a tree ( Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) relates to a composition for preventing or treating skin diseases containing the extract.
아토피성 피부염(Atopic dermatitis, AD)은 가려움증, 피부 건조, 태선화 등의 대표적인 증상을 특징으로 하는 다인성의 염증성 피부질환이다. 아토피 피부염은 외부 알레르겐(allergen)에 의한 면역글로불린 E (immunoglobulin E, IgE) 매개 반응의 유무에 따라 외인성 또는 내인성 아토피 피부염으로 분류된다. 대부분의 아토피 피부염 환자(80% 이상)들은 IgE 반응을 보이는 외인성 아토피 피부염을 가지고 있다. Atopic dermatitis (AD) is a multifactorial inflammatory skin disease characterized by typical symptoms such as itching, skin dryness, and lichenification. Atopic dermatitis is classified as extrinsic or intrinsic atopic dermatitis depending on the presence or absence of an immunoglobulin E (IgE)-mediated reaction caused by an external allergen. Most atopic dermatitis patients (more than 80%) have extrinsic atopic dermatitis that exhibits an IgE response.
외인성 아토피 피부염 환자의 면역학적 특징은 높은 IgE 혈중 수치, Th2 세포 증식, 및 Th2 세포에 의해 생성되는 사이토카인(ex. IL-4)의 높은 혈중 수치를 포함한다. 호염기구(basophils)에 의한 탈과립(degranulation) 또한, 히스타민(histamine)의 혈중 농도를 증가시킨다. Th2 세포와 관련된 면역 반응은 피부 장벽을 약화시키는 것으로 알려져 있다. 이들 세포에서 분비되는 사이토카인, IL-4 및 IL-13은 피부 장벽의 구성요소, 세포 접합에 관여하는 분자 및 세라마이드를 하향 조절한다. 감소된 피부 장벽 기능은 유해한 물질의 침입을 초래할 수 있으며, 피부 수분의 손실은 외인성 아토피 피부염 발병의 주요 동인 중 하나이다. 또한, 피부 장벽 손상으로 인한 알레르겐의 침입의 비효율적인 방지는 알레르겐-유도 염증 반응을 유발한다. Immunological characteristics of patients with extrinsic atopic dermatitis include high blood levels of IgE, Th2 cell proliferation, and high blood levels of cytokines (e.g. IL-4) produced by Th2 cells. Degranulation by basophils also increases blood levels of histamine. Immune responses involving Th2 cells are known to weaken the skin barrier. Cytokines secreted by these cells, IL-4 and IL-13, downregulate components of the skin barrier, molecules involved in cell adhesion, and ceramides. Reduced skin barrier function can lead to the invasion of harmful substances, and loss of skin moisture is one of the main drivers of the development of extrinsic atopic dermatitis. Additionally, ineffective prevention of allergen invasion due to skin barrier damage causes allergen-induced inflammatory responses.
경피 수분 손실(Transepidermal water loss, TEWL)은 아토피 피부염의 중증도에 비례하여 TEWL 값이 증가하므로, 피부 장벽 기능을 측정하는 수단을 제공한다. 내인성 아토피 피부염 환자에게 TEWL 값은 정상수준으로, 이 환자들에게는 두 가지 매커니즘; Th2 세포 및 피부 장벽 손상이 아토피 피부염 발병에 중요한 요소이며, 이들 요소가 서로 영향을 미치며 악순환을 형성한다. 따라서, 아토피성 피부염 환자는 주로 국소 코르티코스테로이드 또는 칼시뉴린 억제제 등을 사용하나, 장기간 사용시 부작용이 나타나는 문제점이 있다.Transepidermal water loss (TEWL) provides a means of measuring skin barrier function, as TEWL values increase in proportion to the severity of atopic dermatitis. In patients with endogenous atopic dermatitis, TEWL values are at normal levels, and in these patients there are two mechanisms; Damage to Th2 cells and skin barrier are important factors in the development of atopic dermatitis, and these factors influence each other to form a vicious cycle. Therefore, patients with atopic dermatitis mainly use topical corticosteroids or calcineurin inhibitors, but there is a problem in that side effects occur when used for a long time.
거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.)는 팥꽃나무과(Thymelaceae)에 속하는 산닥나무속(Genus Wikstroemia)의 낙엽과목으로, 호주, 일본, 한국 남부지역의 고유종이다. 산닥나무속 식물들의 다양한 생리활성에 대해서는 보고되었으나, 거문도닥나무의 생리활성 및 이의 아토피성 피부질환에 대한 치료 효과에 대해서는 보고된 바 없다. Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) is a deciduous tree of the Genus Wikstroemia belonging to the Thymelaceae family, and is an endemic species in Australia, Japan, and southern Korea. Although various physiological activities of plants of the genus Dandelion have been reported, there has been no report on the physiological activity of Geomun ormulberry and its therapeutic effects on atopic skin diseases.
상기와 같은 문제점을 해결하기 위하여, 본 발명의 목적은 부작용이 적고 안전한 천연물 기반의 피부질환 치료제를 제공하는 데에 있다.In order to solve the above problems, the purpose of the present invention is to provide a natural product-based skin disease treatment that is safe and has fewer side effects.
상기의 목적을 달성하기 위하여, 본 발명은 거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) 추출물을 유효성분으로 함유하는, 피부질환 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention Provided is a pharmaceutical composition for preventing or treating skin diseases, containing ganpi (Sieb. et Zucc.) Maxim.) extract as an active ingredient.
본 발명은 거문도닥나무 추출물을 유효성분으로 함유하는, 피부질환 예방 또는 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for preventing or improving skin diseases, which contains an extract of the Korean poplar tree as an active ingredient.
본 발명은 거문도닥나무 추출물을 유효성분으로 함유하는, 피부질환 예방 또는 개선용 의약외품 조성물을 제공한다.The present invention provides a quasi-drug composition for preventing or improving skin diseases, which contains an extract of the Korean poplar tree as an active ingredient.
또한, 본 발명은 본 발명은 거문도닥나무 추출물을 유효성분으로 함유하는, 피부질환 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving skin diseases, which contains an extract of the Korean poplar tree as an active ingredient.
본 발명에 따른 조성물은 천연물인 거문도닥나무 추출물을 유효성분으로 포함하고, 상기 추출물은 우수한 항염증 및 항알레르기 활성을 나타내어 아토피성 피부염, 건선 등의 피부질환을 예방, 개선 또는 치료할 수 있다.The composition according to the present invention contains as an active ingredient a natural product, the extract of the Korean poplar tree, and the extract exhibits excellent anti-inflammatory and anti-allergic activities and can prevent, improve or treat skin diseases such as atopic dermatitis and psoriasis.
상기 조성물은 천연물을 이용함으로써 독성 및 부작용으로부터 안전한 장점이 있다.The composition has the advantage of being safe from toxicity and side effects by using natural products.
도 1은 본 발명의 일 실험예에 따른 거문도닥나무 추출물 처리에 따른 IL-4 발현 수준을 측정한 그래프이다.
도 2는 본 발명의 다른 실험예에 따른 거문도닥나무 추출물 처리에 따른 베타-헥소사미니다아제(β-Hexosaminidase) 분비 수준을 측정한 그래프이다.Figure 1 is a graph measuring the expression level of IL-4 according to treatment with Geomun paper extract according to an experimental example of the present invention.
Figure 2 is a graph measuring the secretion level of beta-hexosaminidase (β-Hexosaminidase) according to treatment with the Korean paper extract according to another experimental example of the present invention.
이하, 본 발명을 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail.
본 발명자들은 in vitro 실험을 통해 우리나라 희귀종인 거문도닥나무의 추출물에서 PI(phorbol 12-myristate 13-acetate/ionomycin) 유도된 RBL-2H3 세포에서 염증성 사이토카인의 억제 활성 및 DNP-IgE로 유도된 RBL-2H3 세포에서 베타-헥소사미니다아제(β-Hexosaminidase) 분비 억제 활성을 확인함으로써, 본 발명을 완성하였다.Through in vitro experiments, the present inventors demonstrated the inhibitory activity of inflammatory cytokines in PI (phorbol 12-myristate 13-acetate/ionomycin)-induced RBL-2H3 cells from extracts of Geomun Dokra, a rare species in Korea, and the inhibitory activity of RBL-2H3 cells induced by DNP-IgE. The present invention was completed by confirming the inhibitory activity of beta-hexosaminidase secretion in 2H3 cells.
본 발명은 거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) 추출물을 유효성분으로 함유하는, 피부질환 예방 또는 치료용 약학 조성물을 제공한다.The present invention is a tree ( Wikstroemia Provided is a pharmaceutical composition for preventing or treating skin diseases, containing ganpi (Sieb. et Zucc.) Maxim.) extract as an active ingredient.
본 명세서에서, "거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.)"는 팥꽃나무과(Thymelaceae)에 속하는 산닥나무속(Genus Wikstroemia) 식물로, 주로, 오스트레일리아, 열대지역인 아시아의 동부·말라야 군도, 대만 및 일본 등지에 분포하며, 우리나라에는 여수, 고흥, 남해, 마산, 부산 등 남부 해안지방에 분포한다.In this specification, " Wikstroemia "ganpi (Sieb. et Zucc.) Maxim.)" is a plant of the Genus Wikstroemia belonging to the Thymelaceae family, and is mainly distributed in Australia, eastern tropical Asia, the Malayan Archipelago, Taiwan, and Japan. , In Korea, it is distributed in southern coastal areas such as Yeosu, Goheung, Namhae, Masan, and Busan.
거문도닥나무는 흔히 숲 가장자리에 자라는 낙엽소관목으로, 높이 1m 내외이며 가지는 원줄기의 아래쪽에서 분지해 총생하고 위쪽에서 원추상으로 많은 소지를 낸다. 당년 가지의 윗부분은 매년 대부분 말라 죽으며, 꽃은 흰색으로 7월~9월에 갈라진 가지 끝과 상부의 엽액에서 짧은 총상화서를 만들고 통상의 꽃이 여러개 달린다. 꽃이 아름답고, 많이 달리며, 식물체의 키가 1m 내외로 조경 및 원예용 소재로의 개발 잠재력이 매우 높은 식물이나, 이의 생리학적 활성에 대한 연구는 미비한 실정이다.Geomun Dokja is a deciduous shrub that commonly grows at the edge of forests. It is about 1m tall. The branches branch and grow in groups at the bottom of the main stem, and produce many cone-shaped branches at the top. Most of the upper part of the current branch dries and dies every year, and the flowers are white, and from July to September, short racemes are produced from the tips of the branched branches and the upper leaf axils, and several regular flowers hang. It has beautiful flowers, grows profusely, and is about 1m tall, so it has great potential for development as a landscaping and horticultural material. However, research on its physiological activity is insufficient.
본 명세서에서, "추출물"이란, 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고 천연물의 성분을 뽑아냄으로써 얻어진 물질을 의미하는 것으로, 천연물의 성분을 뽑아내어 얻어진 물질을 추출 후 다른 방법으로 가공 또는 처리하여 얻어질 수 있는 물질을 모두 포함할 수 있다.In this specification, “extract” refers to a substance obtained by extracting components of a natural product, regardless of the extraction method, extraction solvent, extracted component, or form of the extract. It may include all substances that can be obtained by processing or processing.
상기 거문도닥나무 추출물은 물, C1 내지 C4 알코올 또는 이들의 혼합 용매로 추출된 것일 수 있고, 예를 들어, 메탄올, 에탄올, 프로판올, 부탄올 또는 이의 수용액 등을 상기 용매로 포함할 수 있으나, 이에 제한되는 것은 아니다.The extract of the Korean poplar tree may be extracted with water, C1 to C4 alcohol, or a mixed solvent thereof, and may include, for example, methanol, ethanol, propanol, butanol, or an aqueous solution thereof as the solvent, but is limited thereto. That is not the case.
상기 거문도닥나무 추출물은 거문도닥나무의 뿌리, 나무껍질, 가지, 잎, 꽃, 열매 또는 이들 부위의 혼합물을 추출한 것일 수 있으나, 이에 제한되는 것은 아니다.The extract of Geomun Dolar tree may be extracted from the roots, bark, branches, leaves, flowers, fruits, or mixtures of these parts, but is not limited thereto.
상기 거문도닥나무 추출물은 열수 추출법, 냉침 추출법, 초음파 추출법, 여과법, 환류 추출법 등으로 추출될 수 있으며, 이들은 단독으로 수행되거나 2종 이상의 방법을 병용하여 수행될 수 있으나, 이에 제한되지 않고 당해 기술 분야에서 통상적으로 사용하는 방법 모두를 포함할 수 있다.The Geomun dolphin extract may be extracted by hot water extraction, cold needle extraction, ultrasonic extraction, filtration, reflux extraction, etc., which may be performed alone or in combination of two or more methods, but are not limited thereto and may be used in the art. It can include all commonly used methods.
본 발명에 있어서, 상기 약학 조성물은 염증성 사이토카인, 바람직하게는 IL-4를 억제하고, 비만세포의 탈과립을 억제함으로써, 이와 관련된 피부질환을 예방 또는 치료할 수 있다.In the present invention, the pharmaceutical composition can prevent or treat skin diseases related thereto by inhibiting inflammatory cytokines, preferably IL-4, and degranulation of mast cells.
본 명세서에서, "IL-4 (interleukin 4)"란, 활성화된 비만세포에서 분비되는 Th2 사이토카인으로, 전염증성 신호분자(pro-inflammatory signal molecule)의 발현을 촉진시켜 알레르기 반응을 일으킬 수 있다.As used herein, “IL-4 (interleukin 4)” is a Th2 cytokine secreted from activated mast cells and can cause allergic reactions by promoting the expression of pro-inflammatory signal molecules.
본 발명의 일 실험예에 따르면, PI 유도된 RBL-2H3 세포의 증가된 IL-4가 상기 거문도닥나무 추출물을 처리한 경우, IL-4 발현이 감소되는 것을 확인할 수 있었다.According to an experimental example of the present invention, it was confirmed that IL-4 expression was decreased when PI-induced RBL-2H3 cells were treated with the Lyra Delphinium extract, which increased IL-4.
또한, 본 발명의 다른 실험예에 따르면, IgE로 감작시킨 후, DNP-BSA로 활성화시킨 RBL-2H3 세포의 증가된 탈과립이 상기 거문도닥나무 추출물을 처리한 경우, β-Hexosaminidase 분비가 억제되어 상기 세포의 탈과립이 억제됨을 확인할 수 있었다.In addition, according to another experimental example of the present invention, when RBL-2H3 cells sensitized with IgE and then activated with DNP-BSA were treated with the extract, the increased degranulation of RBL-2H3 cells was suppressed, thereby inhibiting the secretion of β-Hexosaminidase in the cells. It was confirmed that degranulation was suppressed.
상기 피부질환은 알레르기성 또는 염증성 피부질환을 포함할 수 있고, 예를 들면, 아토피성 피부염, 건선, 접촉성 알레르기 피부염, 지루성 피부염, 여드름 및두드러기로 이루어진 군에서 선택되는 어느 하나 이상일 수 있으나, 이에 제한되는 것은 아니다.The skin disease may include allergic or inflammatory skin disease, and may be, for example, any one or more selected from the group consisting of atopic dermatitis, psoriasis, allergic contact dermatitis, seborrheic dermatitis, acne, and urticaria. It is not limited.
이에, 상기 조성물은 피부질환의 예방 또는 치료를 위한 약학 조성물로 활용할 수 있다.Accordingly, the composition can be used as a pharmaceutical composition for preventing or treating skin diseases.
본 명세서에서, "약학 조성물"이란, 특정한 목적을 위해 투여되는 조성물로, 본 발명의 목적상 피부질환, 또는 이의 적어도 하나 이상의 증상을 예방하거나 또는 치료하기 위해 투여되는 것을 의미한다.As used herein, “pharmaceutical composition” means a composition administered for a specific purpose, and for the purpose of the present invention, it is administered to prevent or treat skin disease or at least one symptom thereof.
본 발명에 따른 약학 조성물은 약학적 분야의 통상적인 방법에 따라 제조될 수 있다. 상기 약학 조성물은 제형에 따라 약학적으로 허용가능한 적절한 담체와 배합될 수 있고, 필요에 따라, 부형제, 희석제, 분산제, 유화제, 완충제, 안정제, 결합제, 붕해제, 용제 등을 더 포함하여 제조될 수 있다. 상기 적절한 담체 등은 본 발명에 따른 추출물의 활성 및 특성을 저해하지 않는 것으로, 투여 형태 및 제형에 따라 달리 선택될 수 있다.The pharmaceutical composition according to the present invention can be prepared according to conventional methods in the pharmaceutical field. The pharmaceutical composition may be mixed with an appropriate pharmaceutically acceptable carrier depending on the formulation, and, if necessary, may be prepared by further including excipients, diluents, dispersants, emulsifiers, buffers, stabilizers, binders, disintegrants, solvents, etc. there is. The appropriate carrier does not inhibit the activity and properties of the extract according to the present invention and may be selected differently depending on the dosage form and formulation.
상기 약학 조성물은 어떠한 제형으로도 적용될 수 있고, 보다 상세하게는 통상의 방법에 따라 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 비경구형 제형으로 제형화하여 사용될 수 있다.The pharmaceutical composition can be applied in any formulation, and more specifically, it can be formulated and used in parenteral formulations such as oral formulations, topical preparations, suppositories, and sterile injectable solutions according to conventional methods.
상기 경구형 제형 중 고형 제형은 정제, 환제, 산제, 과립제, 캡슐제 등의 형태로, 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트, 수크로스, 락토오스, 솔비톨, 만니톨, 셀룰로오스, 젤라틴 등을 섞어 조제할 수 있고, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 포함될 수 있다. 또한, 캡술제형의 경우 상기 언급한 물질 외에도 지방유와 같은 액체 담체를 더 포함할 수 있다.Among the oral dosage forms, the solid dosage form is in the form of tablets, pills, powders, granules, capsules, etc., and contains at least one excipient, such as starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, gelatin, etc. It can be prepared by mixing, and in addition to simple excipients, lubricants such as magnesium stearate and talc may also be included. In addition, the capsule formulation may further include a liquid carrier such as fatty oil in addition to the above-mentioned substances.
상기 경구형 제형 중 액상 제형은 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Among the oral dosage forms, liquid dosage forms include suspensions, oral solutions, emulsions, syrups, etc., and may contain various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. in addition to water and liquid paraffin, which are commonly used simple diluents. there is.
상기 비경구 제형은 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. 이에 제한되지 않고, 당해 기술 분야에 알려진 적합한 제제를 모두 사용 가능하다.The parenteral formulation may include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, Tween 61, cacao, laurin, glycerogeratin, etc. can be used. Without being limited thereto, any suitable agent known in the art can be used.
또한, 본 발명에 따른 약학 조성물은 치료 효능의 증진을 위해 칼슘이나 비타민 등을 더 첨가할 수 있다. In addition, the pharmaceutical composition according to the present invention may further add calcium or vitamins to improve therapeutic efficacy.
본 발명에 따른 약학 조성물은 약학적으로 유효한 양으로 투여될 수 있다. The pharmaceutical composition according to the present invention can be administered in a pharmaceutically effective amount.
본 명세서에서, "약학적으로 유효한 양"이란, 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미한다.As used herein, “pharmaceutically effective amount” means an amount that is sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects.
상기 약학 조성물의 유효 용량 수준은 사용 목적, 환자의 연령, 성별, 체중 및 건강 상태, 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 달리 결정될 수 있다. 예를 들어, 일정하지는 않지만 일반적으로 0.001 내지 100mg/kg으로, 바람직하게는 0.01 내지 10mg/kg을 일일 1회 내지 수회 투여될 수 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The effective dosage level of the pharmaceutical composition is determined by the purpose of use, the patient's age, gender, weight and health status, type and severity of the disease, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and excretion rate, treatment. This may vary depending on factors including duration, combination or drugs used simultaneously, and other factors well known in the medical field. For example, although it is not constant, it can be administered generally at 0.001 to 100 mg/kg, preferably at 0.01 to 10 mg/kg once or several times a day. The above dosage does not limit the scope of the present invention in any way.
본 발명에 따른 약학 조성물은 피부질환이 발생할 수 있는 임의의 동물에 투여할 수 있고, 상기 동물은 예를 들어, 인간 및 영장류뿐만 아니라 소, 돼지, 말, 개 등의 가축 등을 포함할 수 있다.The pharmaceutical composition according to the present invention can be administered to any animal that may develop skin disease, and the animals may include, for example, humans and primates, as well as livestock such as cows, pigs, horses, and dogs. .
상기 약학 조성물은 제제 형태에 따른 적당한 투여 경로로 투여될 수 있고, 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있다. 투여 방법은 특히 한정할 필요 없이, 예를 들면, 경구, 직장 또는 정맥, 근육, 피부 도포, 호흡기내 흡입, 자궁내 경막 또는 뇌혈관내(intracere-broventricular) 주사 등의 통상적인 방법으로 투여될 수 있다.The pharmaceutical composition may be administered through an appropriate administration route depending on the formulation type, and may be administered through various oral or parenteral routes as long as it can reach the target tissue. The method of administration does not need to be particularly limited, and may be administered by conventional methods such as oral, rectal or intravenous, intramuscular, or dermal application, intrarespiratory inhalation, intrauterine dural or intracerebroventricular injection, etc. there is.
상기 약학 조성물은 피부질환의 예방 또는 치료를 위하여 단독으로 사용될 수 있고, 수술 또는 다른 약물 치료 등과 병용하여 사용될 수 있다.The pharmaceutical composition can be used alone to prevent or treat skin diseases, or can be used in combination with surgery or other drug treatments.
본 발명은 거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) 추출물을 유효성분으로 함유하는, 피부질환 예방 또는 개선용 화장료 조성물을 제공한다.The present invention is a tree ( Wikstroemia Provided is a cosmetic composition for preventing or improving skin diseases, containing ganpi (Sieb. et Zucc.) Maxim.) extract as an active ingredient.
본 명세서에서, "화장료"란, 피부보호, 피부보습, 아토피성 피부 개선 등의 효과를 가지는 기능성 화장료를 포함할 수 있고, 상기 기능성 화장료는 일반 화장료와 달리 생리활성적인 효능, 효과가 강조된 전문적인 기능성을 갖는 것으로, 피부보호, 피부보습, 아토피성 피부 개선 등 특정 효능과 효과가 강조된 화장료를 의미한다.In this specification, “cosmetics” may include functional cosmetics that have effects such as skin protection, skin moisturizing, and atopic skin improvement. Unlike general cosmetics, the functional cosmetics are professional cosmetics that emphasize bioactive effects and effects. It refers to cosmetics that have functionality and emphasize specific efficacy and effects, such as skin protection, skin moisturizing, and atopic skin improvement.
상기 화장료 조성물은 염증성 사이토카인, 바람직하게는 IL-4를 억제하고, 비만세포의 탈과립을 억제함으로써, 이와 관련된 피부질환을 예방 또는 개선할 수 있다.The cosmetic composition can prevent or improve skin diseases related thereto by inhibiting inflammatory cytokines, preferably IL-4, and inhibiting degranulation of mast cells.
이에 상응하는 특징들은 상술된 부분에서 대신할 수 있다.Corresponding features may be substituted for the parts described above.
본 발명에 따른 화장료 조성물은 식품의약품안전처에 등록된 화장품 원료 리스트 및 ICID(국제화장품 원료집)에 등재되어 있는 성분 중에서 1종 이상을 더 포함할 수 있다. 예를 들어, 상기 화장료 조성물은 유기 용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 방향제, 계면활성제, 유화제, 충전제, 금속이온 봉쇄제, 방부제, 비타민, 차단제, 습윤화제, 염료 및 안료, 친수성 또는 친유성 활성제, 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 하나 이상 더 포함할 수 있다.The cosmetic composition according to the present invention may further include one or more ingredients from the list of cosmetic raw materials registered with the Ministry of Food and Drug Safety and the ingredients listed in the ICID (International Cosmetic Ingredient Directory). For example, the cosmetic composition may include organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, fragrances, surfactants, emulsifiers, fillers, metal ion sequestering agents, preservatives, vitamins, blockers, It may further include one or more auxiliaries commonly used in the cosmetic field, such as wetting agents, dyes and pigments, hydrophilic or lipophilic active agents, or any other ingredients commonly used in cosmetics.
상기 비타민은 수용성 또는 유용성 비타민을 포함할 수 있고, 상기 수용성 비타민은 수용성 비타민으로서 화장품에 배합 가능한 것으로, 바람직하게는 비타민 B1, 비타민 B2, 비타민 B6, 피리독신, 염산피리독신, 비타민 B12, 판토텐산, 니코틴산, 니코틴산아미드, 엽산, 비타민C, 비타민 H 등을 들 수 있다. 또한, 그들의 염 (티아민염산염, 아스코르빈산나트륨염 등)이나 유도체(아스코르빈산-2-인산나트륨염, 아스코르빈산-2-인산마그네슘염 등)도 포함될 수 있고, 상기 수용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 수득될 수 있다.The vitamins may include water-soluble or oil-soluble vitamins, and the water-soluble vitamins are water-soluble vitamins that can be mixed into cosmetics, and are preferably vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, Examples include nicotinic acid amide, folic acid, vitamin C, and vitamin H. In addition, their salts (thiamine hydrochloride, sodium ascorbate, etc.) or derivatives (sodium ascorbic acid-2-phosphate, magnesium ascorbic acid-2-phosphate, etc.) may also be included, and the water-soluble vitamins may be prepared by microbial transformation. , can be obtained by conventional methods such as purification from microbial cultures, enzyme methods, or chemical synthesis.
본 발명에 따른 화장료 조성물은 본 발명이 속하는 기술 분야에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 화장수, 유액, 로션, 크림, 페이스트, 젤, 용액, 현탁액, 오일, 왁스, 팩, 파우더, 파운데이션, 스프레이, 계면활성제-함유 클렌징 등으로 제형화 될 수 있으나, 이에 제한되는 것은 아니다. The cosmetic composition according to the present invention can be manufactured in any formulation commonly manufactured in the technical field to which the present invention pertains. For example, it may be formulated as lotion, emulsion, lotion, cream, paste, gel, solution, suspension, oil, wax, pack, powder, foundation, spray, surfactant-containing cleansing, etc., but is not limited thereto. .
더욱 상세하게는, 유연 화장수, 영양 화장수, 수렴 화장수, 영양 크림, 마사지 크림, 밀크 로션, 파우더, 에센스, 아이 크림, 선로션, 선크림, 메이크업 프라이머, 메이크업 베이스, 비비크림, 분말 파운데이션, 유탁액 파운데이션, 클렌징크림, 클렌징폼, 클렌징 워터, 비누, 팩, 스틱상 제품, 밤(Balm) 타입 제품, 스프레이 또는 파우더의 제형으로 제조될 수 있다.More specifically, flexible lotion, nourishing lotion, astringent lotion, nourishing cream, massage cream, milk lotion, powder, essence, eye cream, sun lotion, sunscreen, makeup primer, makeup base, BB cream, powder foundation, emulsion foundation. , cleansing cream, cleansing foam, cleansing water, soap, pack, stick product, balm type product, spray, or powder.
상기 화장료 조성물이 크림 또는 젤 제형인 경우에는 담체 성분으로 동물성유, 식물성유, 왁스, 파라핀, 전분, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등을 더 포함할 수 있다.When the cosmetic composition is a cream or gel formulation, it may further include animal oil, vegetable oil, wax, paraffin, starch, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide as carrier ingredients.
상기 화장료 조성물이 용액 또는 유탁액 제형인 경우에는 용매, 용매화제 또는 유탁화제로, 물, 에탄올, 이소프로판올, 에틸카보네이트, 에틸아세테이트, 벤질알코올, 프로필렌글리콜, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르 등을 더 포함할 수 있다.When the cosmetic composition is in the form of a solution or emulsion, the solvent, solvating agent, or emulsifying agent may be water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, propylene glycol, glycerol aliphatic ester, polyethylene glycol, or fatty acid of sorbitan. It may further include ester, etc.
상기 화장료 조성물이 현탁액 제형인 경우에는 담체 성분으로 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등을 더 포함할 수 있다.When the cosmetic composition is a suspension formulation, the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and microcrystalline It may further include cellulose, aluminum metahydroxide, bentonite, agar, or tracant.
상기 화장료 조성물이 파우더 또는 스프레이 제형인 경우에는 담체 성분으로 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더를 더 포함할 수 있고, 특히 스프레이 제형인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸에테르와 같은 추진체를 더 포함할 수 있다.When the cosmetic composition is in a powder or spray formulation, it may further include lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder as a carrier ingredient, and especially in the case of a spray formulation, it may additionally include chlorofluorohydrocarbon. , may further include a propellant such as propane/butane or dimethyl ether.
상기 화장료 조성물이 계면활성제-함유 클렌징 제형인 경우에는 담체 성분으로 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등을 더 포함할 수 있다.When the cosmetic composition is a surfactant-containing cleansing formulation, the carrier ingredients include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, and fatty acid amide. It may further include ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linoline derivative, or ethoxylated glycerol fatty acid ester.
본 발명에 따른 화장료 조성물은 단독 또는 중복으로 도포하여 사용하거나, 본 발명 이외의 다른 화장료 조성물과 중복 도포하여 사용할 수 있다. 또한, 본 발명에 따른 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.The cosmetic composition according to the present invention can be used individually or by applying it in duplicate, or can be used by applying it in duplicate with other cosmetic compositions other than the present invention. In addition, the cosmetic composition according to the present invention can be used according to conventional usage methods, and the number of times of use can be varied depending on the user's skin condition or preference.
본 발명은 거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) 추출물을 유효성분으로 함유하는, 피부질환 예방 또는 개선용 의약외품 조성물을 제공한다.The present invention is a tree ( Wikstroemia Provided is a quasi-drug composition for preventing or improving skin diseases, containing ganpi (Sieb. et Zucc.) Maxim.) extract as an active ingredient.
본 명세서에서, "의약외품"이란 사람이나 동물의 질병을 치료, 경감, 처치 또는 예방할 목적으로 사용되는 섬유, 고무제품 또는 이와 유사한 것, 인체에 대한 작용이 약하거나 인체에 직접 작용하지 아니하며, 기구 또는 기계가 아닌 것과 이와 유사한 것, 감염형 예방을 위하여 살균, 살충 및 이와 유사한 용도로 사용되는 제제 중 하나에 해당하는 물품으로서, 본 발명에 따른 의약외품 조성물은 바람직하게는 피부외용제 의약외품을 포함할 수 있다.In this specification, “quasi-drugs” refer to fibers, rubber products, or similar products used for the purpose of treating, alleviating, treating, or preventing diseases in humans or animals; they have a weak effect on the human body or do not act directly on the human body; As an article that is one of the non-machine and similar products and preparations used for sterilization, insecticide and similar purposes to prevent infections, the quasi-drug composition according to the present invention may preferably include a quasi-drug for external use on the skin. .
상기 의약외품 조성물은 염증성 사이토카인, 바람직하게는 IL-4를 억제하고, 비만세포의 탈과립을 억제함으로써, 이와 관련된 피부질환을 예방 또는 개선할 수 있다.The quasi-drug composition can prevent or improve skin diseases related thereto by inhibiting inflammatory cytokines, preferably IL-4, and degranulation of mast cells.
이에 상응하는 특징들은 상술된 부분에서 대신할 수 있다.Corresponding features may be substituted for the parts described above.
본 발명에 따른 의약외품 조성물은 상기 유효성분 이외에 피부외용제 의약외품 조성물에 통상적으로 이용되는 성분들을 더 포함할 수 있고, 예를 들어, 연마제, 습윤제, 결합제, 기포제, 감미제, 방부제, 약효성분, 향미제, 색소, 용제, 증백제, 가용화제 또는 pH 조정제를 포함할 수 있다.In addition to the above active ingredients, the quasi-drug composition according to the present invention may further include ingredients commonly used in quasi-drug compositions for external use on the skin, for example, abrasives, wetting agents, binders, foaming agents, sweeteners, preservatives, medicinal ingredients, flavoring agents, It may contain colorants, solvents, brighteners, solubilizers, or pH adjusters.
상기 의약외품 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 소독 청결제, 샤워폼, 연고액, 물티슈, 코팅제, 마스크, 안대, 붕대 등을 포함할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition may be manufactured in any formulation commonly manufactured in the art, and may include, but is limited to, disinfectant cleaners, shower foams, ointments, wet tissues, coatings, masks, eye patches, and bandages, for example. This does not mean that the formulation method, dosage, usage method, components, etc. of the quasi-drug may be appropriately selected from conventional techniques known in the technical field.
상기 의약외품 조성물은 단독 또는 중복하여 사용하거나, 본 발명 이외의 다른 의약외품 조성물과 중복하여 사용할 수 있다.The above quasi-drug composition may be used alone or in combination, or may be used in combination with other quasi-drug compositions other than the present invention.
본 발명은 본 발명은 거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) 추출물을 유효성분으로 함유하는, 피부질환 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention relates to the present invention . Provided is a health functional food composition for preventing or improving skin diseases, containing ganpi (Sieb. et Zucc.) Maxim.) extract as an active ingredient.
본 명세서에서, "건강기능식품"이란, 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 포함하며, 영양 공급 외에도 본 발명의 목적상 아토피성 피부염 등의 피부질환의 예방, 생체 방어, 면역, 회복 등의 생체 조절 기능이 효율적으로 나타나도록 가공된 의학, 의료 효과가 높은 식품을 의미한다.In this specification, “health functional food” includes food manufactured and processed using raw materials or ingredients with functionality useful to the human body pursuant to Act No. 6727 on Health Functional Food, and is the object of the present invention in addition to nutritional supply. It refers to foods with high medical effects that have been processed to efficiently exhibit biological control functions such as prevention of skin diseases such as atopic dermatitis, biological defense, immunity, and recovery.
상기 건강기능식품 조성물은 염증성 사이토카인, 바람직하게는 IL-4를 억제하고, 비만세포의 탈과립을 억제함으로써, 이와 관련된 피부질환을 예방 또는 개선할 수 있다.The health functional food composition can prevent or improve skin diseases related thereto by inhibiting inflammatory cytokines, preferably IL-4, and inhibiting degranulation of mast cells.
이에 상응하는 특징들은 상술된 부분에서 대신할 수 있다.Corresponding features may be substituted for the parts described above.
본 발명에 따른 건강기능식품 조성물에 있어서, 상기 건강기능식품은 피부질환의 예방 또는 개선 목적으로, 분말, 과립, 정제, 캡슐, 시럽 또는 음료 등으로 제조될 수 있다. 상기 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 상기 약학 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가될 수 있다. In the health functional food composition according to the present invention, the health functional food may be manufactured into powder, granule, tablet, capsule, syrup or beverage for the purpose of preventing or improving skin diseases. There is no limit to the form that the health functional food can take, and it can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods.
상기 건강기능식품은 통상적인 의미의 식품을 모두 포함할 수 있다. 예를 들어, 음료 및 각종 드링크, 과실 및 그의 가공식품(과일통조림, 잼 등), 어류, 육류 및 그 가공식품(햄, 베이컨 등), 빵류 및 면류, 쿠키 및 스낵류, 유제품(버터, 치즈 등) 등이 가능하며, 통상적인 의미에서의 기능성 식품을 모두 포함할 수 있다. 또한, 동물을 위한 사료로 이용되는 식품도 포함할 수 있다.The health functional food may include all foods in the conventional sense. For example, beverages and various drinks, fruits and their processed foods (canned fruit, jam, etc.), fish, meat and their processed foods (ham, bacon, etc.), breads and noodles, cookies and snacks, dairy products (butter, cheese, etc.) ), etc. are possible, and can include all functional foods in the conventional sense. It may also include food used as feed for animals.
또는, 본 발명에 따른 건강기능식품은 이너뷰티 푸드(inner beauty food)일 수 있다. Alternatively, the health functional food according to the present invention may be inner beauty food.
본 명세서에서, "이너뷰티(inner beauty)"란, 내면의(inner) 아름다움(beauty)을 뜻하며, 화장품을 바르는 등 인위적인 방법으로 피부 표면만을 일시적으로 좋게 만드는 것이 아니라, 식품 등을 통해 피부 속, 내부에서부터 건강한 피부를 가꾸는 것을 의미한다.In this specification, "inner beauty" refers to inner beauty, and does not only temporarily improve the surface of the skin through artificial methods such as applying cosmetics, but also improves the inner and outer skin of the skin through food, etc. It means taking care of healthy skin from the inside.
상기 이너뷰티 푸드는 연화제, 항산화제, 현탁화제, 발포제, 계면활성제, 정제수, 이온형 또는 비이온형 유화제, 충전제, 보존제, 비타민, 차단제, 습윤화제, 염료, 안료, 친수성 또는 친유성 활성제 중에서 선택된 어느 하나 이상의 보조제를 추가로 포함할 수 있으나, 이에 제한되지 않고, 약학적으로 허용가능한 약학 보조제, 식품학적으로 허용가능한 식품 보조제, 생물학적 활성 화합물, 흡수성 물질, 퍼스널 케어 화합물(personal care compound), 활성 성분, 미용 보조제 중 어느 하나 또는 이들의 조합을 더 포함할 수 있다.The inner beauty food is selected from softeners, antioxidants, suspending agents, foaming agents, surfactants, purified water, ionic or non-ionic emulsifiers, fillers, preservatives, vitamins, blocking agents, wetting agents, dyes, pigments, and hydrophilic or lipophilic active agents. It may further include one or more adjuvants, but is not limited thereto, pharmaceutically acceptable pharmaceutical adjuvants, foodologically acceptable food adjuvants, biologically active compounds, absorbent materials, personal care compounds, active ingredients. It may further include any one of ingredients and beauty aids or a combination thereof.
상기 이너뷰티 푸드는 구강 점막용 필름, 정제, 시럽, 캡슐, 환제, 과립, 분말, 에어로졸 중에서 선택된 어느 하나 이상의 제형으로 이루어질 수 있으나, 이에 제한되는 것은 아니다.The inner beauty food may be made of one or more formulations selected from films for oral mucosa, tablets, syrups, capsules, pills, granules, powders, and aerosols, but is not limited thereto.
본 발명에 따른 건강기능식품 조성물은 당업계에서 통상적으로 사용되는 식품학적으로 허용 가능한 식품 첨가제(식품 첨가물) 및 적절한 기타 보조 성분을 더 포함하여 제조될 수 있다. 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정할 수 있다. 상기 '식품첨가물공전'에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료 제제, 타르색소제제 등의 혼합 제제류 등을 들 수 있다. The health functional food composition according to the present invention may be prepared by further including foodologically acceptable food additives (food additives) commonly used in the art and other appropriate auxiliary ingredients. Unless otherwise specified, suitability as a food additive can be determined in accordance with the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the food additive code approved by the Ministry of Food and Drug Safety. Items listed in the 'Food Additives Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark pigment, licorice extract, crystalline cellulose, high-quality pigment, and guar gum; Mixed preparations such as L-glutamate sodium preparations, noodle additive alkaline preparations, preservative preparations, and tar coloring preparations can be mentioned.
상기 기타 보조 성분은 예를 들어, 향미제, 천연 탄수화물, 감미제, 비타민, 전해질, 착색제, 펙트산, 알긴산, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산화제 등을 추가로 함유할 수 있다. 특히, 상기 천연 탄수화물로는 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로오스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜을 사용할 수 있으며, 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The other auxiliary ingredients include, for example, flavoring agents, natural carbohydrates, sweeteners, vitamins, electrolytes, colorants, pectic acid, alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents, etc. It may additionally contain. In particular, the natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. , Natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used as sweeteners.
본 발명에 따른 건강기능식품에 함유된 상기 추출물의 유효 용량은 피부질환의 예방 또는 개선 등 그 사용 목적에 따라 적절하게 조절될 수 있다. The effective dose of the extract contained in the health functional food according to the present invention can be appropriately adjusted depending on the purpose of use, such as preventing or improving skin diseases.
상기 건강기능식품 조성물은 식품을 원료로 하여 일반 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 피부질환의 예방 또는 개선을 위한 보조제로 섭취될 수 있다.The health functional food composition is made from food and has the advantage of having no side effects that may occur when taking regular drugs for a long period of time, and is highly portable, so it can be consumed as an adjuvant for preventing or improving skin diseases.
또한, 본 발명은 거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.) 추출물을 유효성분으로 함유하는, 베타-헥소사미니다아제(β-Hexosaminidase) 분비 억제용 시약 조성물을 제공한다.In addition, the present invention is a tree ( Wikstroemia Provided is a reagent composition for inhibiting secretion of beta-hexosaminidase, containing an extract of ganpi (Sieb. et Zucc.) Maxim.) as an active ingredient.
이에 상응하는 특징들은 상술된 부분에서 대신할 수 있다.Corresponding features may be substituted for the parts described above.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, the present invention will be described in detail through examples to aid understanding. However, the following examples only illustrate the content of the present invention and the scope of the present invention is not limited to the following examples. Examples of the present invention are provided to more completely explain the present invention to those skilled in the art.
<< 준비예Preparation example 1> 거문도닥나무 추출물 제조 1> Manufacture of Geomun paper extract
거문도닥나무(Wikstroemia ganpi (Sieb. et Zucc.) Maxim.)의 지상부는 대한민국 전라남도 고흥군 영남면 금사리에서 채집되었으며, 백진협(한국생명공학연구원 해외생물소재연구센터)에 의해 동정되었다. 증거 표본(voucher specimen, KRIB 0088571)은 한국생명공학연구원 표본관(KRIB)에 보관하였다. Wikstroemia The aerial part of ganpi (Sieb. et Zucc.) Maxim.) was collected from Geumsa-ri, Yeongnam-myeon, Goheung-gun, Jeollanam-do, South Korea, and was identified by Baek Jin-hyeop (Korea Research Institute of Bioscience and Biotechnology, Overseas Biomaterials Research Center). The voucher specimen (KRIB 0088571) was stored in the Korea Research Institute of Bioscience and Biotechnology Herbarium (KRIB).
거문도닥나무 시료 (건조 식물 21g)를 2L 부피의 물 (0% 에탄올), 30% 에탄올, 95% 에탄올로 냉침, 초음파 및 환류 추출하여 여과한 후, 35℃ 진공에서 증발시켜 반고체 잔류물을 얻은 다음, 이를 동결시켰다.A sample (21 g of dried plant) of Geomun dolphin was filtered by cold immersion, ultrasound, and reflux extraction with 2 L of water (0% ethanol), 30% ethanol, and 95% ethanol, and then evaporated in a vacuum at 35°C to obtain a semi-solid residue. , which was frozen.
이로써, 0% 에탄올 냉침 추출물, 30% 에탄올 냉침 추출물, 95% 에탄올 냉침 추출물, 0% 에탄올 초음파 추출물, 30% 에탄올 초음파 추출물, 95% 에탄올 초음파 추출물, 0% 에탄올 환류 추출물, 30% 에탄올 환류 추출물 및 95% 에탄올 환류 추출물을 제조하였다.Hereby, 0% ethanol cold steeping extract, 30% ethanol cold steeping extract, 95% ethanol cold steeping extract, 0% ethanol ultrasonic extract, 30% ethanol ultrasonic extract, 95% ethanol ultrasonic extract, 0% ethanol reflux extract, 30% ethanol reflux extract and A 95% ethanol reflux extract was prepared.
<< 실험예Experiment example 1> 거문도닥나무 추출물의 PI [포볼 12- 1> PI of Korean paper extract [Phorbol 12- 미리스테이트myristate 13-아세테이트(phorbol 12- 13-acetate (phorbol 12- myristatemyristate 13-acetate, 13-acetate, PMAPMA ) / ) / 이오노마이신Ionomycin (( IonomycinIonomycin )] 유도성 IL-4 발현 억제능 확인)] Confirmed ability to suppress inducible IL-4 expression
활성화된 비만 세포에서 분비되는 Th2 사이토카인인 IL-4 등은 전염증성 신호분자(pro-inflammatory signal molecule) 발현을 촉진시켜 알러지 반응을 일으킨다고 알려져 있다. 이에, 상기 준비예 1에 따라 다양한 조건에서 추출한 거문도닥나무 추출물(0% 에탄올 냉침, 30% 에탄올 냉침, 95% 에탄올 냉침, 0% 에탄올 초음파, 30% 에탄올 초음파, 95% 에탄올 초음파, 0% 에탄올 환류, 30% 에탄올 환류, 95% 에탄올 환류)이 RBL-2H3 세포에서 PI로 유도된 IL-4의 발현에 미치는 영향을 확인하였다.IL-4, a Th2 cytokine secreted from activated mast cells, is known to cause allergic reactions by promoting the expression of pro-inflammatory signal molecules. Accordingly, according to Preparation Example 1, the extract of Geomun dolphin extracted under various conditions (0% ethanol cold immersion, 30% ethanol cold immersion, 95% ethanol cold immersion, 0% ethanol ultrasonic waves, 30% ethanol ultrasonic waves, 95% ethanol ultrasonic waves, 0% ethanol reflux) , 30% ethanol reflux, 95% ethanol reflux) on the expression of IL-4 induced by PI in RBL-2H3 cells was confirmed.
먼저, 래트 호염기성 백혈병 세포(Rat basophilic leukemia cell)인 RBL-2H3 세포와 마우스 유래 T 세포주인 EL4 세포는 한국세포주은행(Korea Cell Line Bank; Seoul, Korea)에서 분양받아 사용하였고, 10% 소태아혈청(fetal bovine serum, FBS; HyClone Laboratories, Logan, UT, USA)과 1% 페니실린-스트렙토마이신(penicillin-streptomycin, PS; Hyclone)이 첨가된 DMEM(Dulbecco's modified Eagle Medium; Hyclone) 배지에서 37℃, 5% CO2 조건하에 배양하였다. First, RBL-2H3 cells, a rat basophilic leukemia cell, and EL4 cells, a mouse-derived T cell line, were purchased from Korea Cell Line Bank (Seoul, Korea) and used, and 10% bovine fetus cells were used. 37°C in DMEM (Dulbecco's modified Eagle Medium; Hyclone) supplemented with serum (fetal bovine serum, FBS; HyClone Laboratories, Logan, UT, USA) and 1% penicillin-streptomycin (PS; Hyclone); Cultured under 5% CO 2 conditions.
6-웰 플레이트에 RBL-2H3 세포 5×105 cells/well의 밀도로 분주한 뒤 배양기에서 16시간 배양한 후, 상기 준비예 1의 여러 가지 추출물(10μg/ml)을 1시간 동안 반응시켰다. 이후, 최종농도 50 ng/ml의 PMA(phorbol 12-myristate 13-acetate)와 1μM 이오노마이신(Ionomycin); (PI)을 가하여 8시간 반응시키고, PBS로 세척한 후 easy-BlueTM total RNA extraction kit(iNTRON Biotechnology, Seoul, Korea)를 사용하여 total RNA를 추출하였다. 추출한 RNA는 Agilent 2100 BioAnalyzer(Agilent Technologies, SantaClara, CA, USA)를 사용하여 integrity를 확인하였다. cDNA는 ImProm-II Reverse Transcription System(Promega, Madison, WI,USA)을 이용하여 합성하였으며, PCR은 GeneAmp PCR System 9700(Applied Biosystems, Foster City, CA, USA)을 사용하여 수행하였다. PCR 산물은 1.5% 아가로스 겔(agarose gel)에서 전기 영동한 후 유전자 발현 정도를 알아보았으며, 밴드의 강도는 SigmaGel(Jandel Scientific, san Fafael, CA, USA) 소프트웨어에 의해 분석 정량하였다. RBL-2H3 cells were distributed in a 6-well plate at a density of 5 × 10 5 cells/well, cultured in an incubator for 16 hours, and various extracts (10 μg/ml) of Preparation Example 1 were reacted for 1 hour. Thereafter, PMA (phorbol 12-myristate 13-acetate) and 1 μM ionomycin (Ionomycin) at a final concentration of 50 ng/ml; (PI) was added and reacted for 8 hours, washed with PBS, and total RNA was extracted using the easy-BlueTM total RNA extraction kit (iNTRON Biotechnology, Seoul, Korea). The integrity of the extracted RNA was confirmed using an Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA). cDNA was synthesized using the ImProm-II Reverse Transcription System (Promega, Madison, WI, USA), and PCR was performed using the GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA). The PCR product was subjected to electrophoresis on a 1.5% agarose gel to determine the level of gene expression, and the intensity of the band was analyzed and quantified using SigmaGel (Jandel Scientific, San Fafael, CA, USA) software.
사용된 프라이머 염기서열은 하기 표 1과 같다.The primer base sequences used are shown in Table 1 below.
IL-4
IL-4
β-actin
β-actin
Th2 세포 분화 조절에 대한 작용기전을 조사하기 위해, 6-웰 플레이트에 EL4 세포 5×105 cells/well의 밀도로 분주한 뒤 배양기에서 24시간 배양한 후, 상기 준비예 1의 여러 가지 추출물들(10μg/ml)을 1시간 동안 반응시켰다. 이후 PMA 1 ng/ml와 4-터트-옥틸페놀(4-tert-Octylphenol, OP; Sigma, USA) 5 Um/ml를 가하여 24시간 반응시키고, 상층액의 IL-4 양을 ELISA 방법으로 측정하였다.To investigate the mechanism of action for regulating Th2 cell differentiation, EL4 cells were seeded at a density of 5 × 10 5 cells/well in a 6-well plate and cultured in an incubator for 24 hours, and then various extracts of Preparation Example 1 above were added. (10μg/ml) was reacted for 1 hour. Afterwards, 1 ng/ml of PMA and 5 Um/ml of 4-tert-Octylphenol (OP; Sigma, USA) were added and reacted for 24 hours, and the amount of IL-4 in the supernatant was measured by ELISA method. .
그 결과, 도 1에 나타난 바와 같이, PI 유도에 의해 활성화된 세포에서 IL-4가 3배 가까이 증가하는 것을 확인하였으며, 추출물을 10μg/ml로 처리하였을 때 이러한 IL-4 mRNA 발현 증가가 30% 에탄올 냉침 > 30% 에탄올 초음파 > 0% 에탄올 냉침의 순서로 억제되는 것을 확인하였다.As a result, as shown in Figure 1, it was confirmed that IL-4 increased nearly 3-fold in cells activated by PI induction, and when the extract was treated at 10 μg/ml, this increase in IL-4 mRNA expression was 30%. It was confirmed that the inhibition occurred in the following order: ethanol cold immersion > 30% ethanol ultrasound > 0% ethanol cold immersion.
<< 실험예Experiment example 2> 거문도닥나무 추출물의 세포에서 베타- 2> Beta- in the cells of the Korean paper extract 헥소나미니다아제hexonaminidase (β-hexosaminidase) 분비 억제능 확인(β-hexosaminidase) secretion inhibition ability confirmed
베타-헥소사미니다아제(β-Hexosaminidase)는 비만세포나 호염구의 과립 안에 존재하며 천식, 비염과 같은 알러지 반응에 의해 세포 밖으로 분비되어 탈과립의 지표로 이용되고, 알러지 억제물질의 생리활성 측정에 유용하게 사용되고 있다. Beta-hexosaminidase exists in the granules of mast cells or basophils and is secreted out of the cell by allergic reactions such as asthma and rhinitis, and is used as an indicator of degranulation and is useful for measuring the physiological activity of allergy suppressants. It is being used extensively.
RBL-2H3 세포로부터 탈과립화 측정은 탈과립의 바이오마커인 베타-헥소사미니다아제 분비 저해 활성을 측정하여 조사하였다. 0.5μg/ml 농도의 디니트로페닐-면역글로불린 E(dinitropheny-immunoglobulin E, DNP-IgE)를 함유한 DMEM 배지를 사용하여, 24-웰 플레이트에 RBL-2H3 세포를 2×105 cells/well의 밀도로 분주한 뒤, 37℃, 5% CO2 인큐베이터에서 12시간 배양하였다. 각 세포들을 Siraganian buffer (119 mM NaCl, 5 mM KCl, 5.6 mM glucose, 0.4 mM MgCl2, 25 mM PIPES, 1 mM CaCl2, 0.1% BSA, pH 7.2)로 2회 세척 한 다음, 37℃, 5% CO2 인큐베이터에서 동일 buffer로 10분간 전 배양한 후 추출물을(10μg/ml)로 희석시켜 세포에 처리하여 37℃, 5% CO2 인큐베이터에서 30분 동안 반응시켰다. 이후 DNP-소혈청알부민(bovine serum albumin) (DNP-BSA)을 최종 농도 100μg/ml이 되도록 가하여 37℃, 5% CO2 인큐베이터에서 2시간 반응시키고, ice bath에서 10분간 배양한 후 반응을 종결시켰다. 상층액 40μl를 96-웰 플레이트에 옮기고 substrate buffer (2 mM 4-p-nitrophenyl-N-acetyl-β-D-glucosaminide, 0.05 M Sodium citrate, pH 4.5) 40μl를 가하고 37℃에서 1시간 동안 배양시킨 다음 각 웰 당 stop solution (0.1 M Na2CO3/NaHCO3, pH 10.5) 200 μl를 첨가하여 반응을 종결시키고 405 nm에서 흡광도를 측정하였다.Degranulation from RBL-2H3 cells was measured by measuring beta-hexosaminidase secretion inhibitory activity, a biomarker of degranulation. Using DMEM medium containing dinitropheny-immunoglobulin E (DNP-IgE) at a concentration of 0.5 μg/ml, RBL-2H3 cells were grown in 24-well plates at 2 × 10 5 cells/well. After dispensing according to density, the cells were cultured in an incubator at 37°C and 5% CO 2 for 12 hours. Each cell was washed twice with Siraganian buffer (119mM NaCl, 5mM KCl, 5.6mM glucose, 0.4mM MgCl2 , 25mM PIPES, 1mM CaCl2 , 0.1% BSA, pH 7.2) and then incubated at 37°C for 5 days. After pre-incubation with the same buffer in a % CO 2 incubator for 10 minutes, the extract was diluted to (10 μg/ml), treated with cells, and reacted for 30 minutes in a 5% CO 2 incubator at 37°C. Afterwards, DNP-bovine serum albumin (DNP-BSA) was added to a final concentration of 100 μg/ml, reacted for 2 hours in a 5% CO 2 incubator at 37°C, and incubated in an ice bath for 10 minutes to terminate the reaction. I ordered it. 40 μl of the supernatant was transferred to a 96-well plate, 40 μl of substrate buffer (2 mM 4-p-nitrophenyl-N-acetyl-β-D-glucosaminide, 0.05 M Sodium citrate, pH 4.5) was added, and incubated at 37°C for 1 hour. Next, 200 μl of stop solution (0.1 M Na 2 CO 3 /NaHCO 3 , pH 10.5) was added to each well to terminate the reaction, and the absorbance was measured at 405 nm.
RBL-2H3 세포를 IgE로 먼저 감작시킨 후, DNP-BSA로 활성화시키고, 다양한 조건에서 추출한 거문도닥나무 추출물(0% 에탄올 냉침, 30% 에탄올 냉침, 95% 에탄올 냉침, 0% 에탄올 초음파, 30% 에탄올 초음파, 95% 에탄올 초음파, 0% 에탄올 환류, 30% 에탄올 환류, 95% 에탄올 환류)의 탈과립 억제 여부를 측정한 결과, 도 2에 나타난 바와 같이, IgE와 DNP-BSA에 의해 RBL-2H3 세포는 무처리군에 비해 약 1.8배 정도 탈과립이 증가하였으며, 30% 에탄올 냉침 > 30% 에탄올 초음파 > 0% 에탄올 냉침의 순서로 탈과립 억제능이 큰 것으로 나타났다. RBL-2H3 cells were first sensitized with IgE, then activated with DNP-BSA, and then treated with Geomoonsis extract extracted under various conditions (0% ethanol cold immersion, 30% ethanol cold immersion, 95% ethanol cold immersion, 0% ethanol ultrasound, 30% ethanol As a result of measuring whether degranulation was inhibited by ultrasound, 95% ethanol ultrasound, 0% ethanol reflux, 30% ethanol reflux, and 95% ethanol reflux), as shown in Figure 2, RBL-2H3 cells were inhibited by IgE and DNP-BSA. Degranulation increased by approximately 1.8 times compared to the untreated group, and the degranulation inhibition ability was found to be greater in the following order: 30% ethanol cold immersion > 30% ethanol ultrasound > 0% ethanol cold immersion.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 즉, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다.As the specific parts of the present invention have been described in detail above, it is clear to those skilled in the art that these specific techniques are merely preferred embodiments and do not limit the scope of the present invention. do. That is, the practical scope of the present invention is defined by the appended claims and their equivalents.
<110> Pusan National University Industry-University Cooperation Foundation Korea Research Institute of Bioscience and Biotechnology <120> COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES COMPRISING WIKSTROEMIA GANPI <130> ADP-2021-0347 <160> 4 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> IL-4 -f <400> 1 accttgctgt caccctgttc 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> IL-4 -r <400> 2 ttgtgagcgt ggactcattc 20 <210> 3 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> beta-actin -f <400> 3 tcatcaccat cggcaacg 18 <210> 4 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> beta-actin -r <400> 4 ttcctgatgt ccacgtcgc 19 <110> Pusan National University Industry-University Cooperation Foundation Korea Research Institute of Bioscience and Biotechnology <120> COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES COMPRISING WIKSTROEMIA GANPI <130> ADP-2021-0347 <160> 4 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> IL-4 -f <400> 1 accttgctgt caccctgttc 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> IL-4 -r <400> 2 ttgtgagcgt ggactcattc 20 <210> 3 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> beta-actin -f <400> 3 tcatcaccat cggcaacg 18 <210> 4 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> beta-actin -r <400> 4 ttcctgatgt ccacgtcgc 19
Claims (9)
상기 추출물은,
물, C1 내지 C4 알코올 또는 이들의 혼합 용매로 추출된 것을 특징으로 하는, 약학 조성물.According to claim 1,
The extract is,
A pharmaceutical composition, characterized in that it is extracted with water, C1 to C4 alcohol, or a mixed solvent thereof.
상기 약학 조성물은,
염증성 사이토카인을 억제하는 것을 특징으로 하는, 약학 조성물.According to claim 1,
The pharmaceutical composition is,
A pharmaceutical composition, characterized in that it inhibits inflammatory cytokines.
상기 약학 조성물은,
비만세포의 탈과립을 억제하는 것을 특징으로 하는, 약학 조성물.According to claim 1,
The pharmaceutical composition is,
A pharmaceutical composition, characterized in that it inhibits degranulation of mast cells.
상기 건강기능식품은,
이너뷰티 푸드(inner beauty food)인 것을 특징으로 하는, 건강기능식품 조성물.According to claim 8,
The health functional food is,
A health functional food composition, characterized in that it is an inner beauty food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210104511A KR102642293B1 (en) | 2021-08-09 | 2021-08-09 | Composition for preventing or treating skin diseases comprising wikstroemia ganpi |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210104511A KR102642293B1 (en) | 2021-08-09 | 2021-08-09 | Composition for preventing or treating skin diseases comprising wikstroemia ganpi |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230022571A KR20230022571A (en) | 2023-02-16 |
| KR102642293B1 true KR102642293B1 (en) | 2024-02-29 |
Family
ID=85325736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210104511A KR102642293B1 (en) | 2021-08-09 | 2021-08-09 | Composition for preventing or treating skin diseases comprising wikstroemia ganpi |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102642293B1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120003171A (en) | 2010-07-02 | 2012-01-10 | (주)아모레퍼시픽 | Cosmetic composition containing broussonetia extract for moisturizing the skin |
-
2021
- 2021-08-09 KR KR1020210104511A patent/KR102642293B1/en active IP Right Grant
Non-Patent Citations (3)
| Title |
|---|
| Biomolecules; 2019; 9(11); 697-709 |
| 김태영; 부산대학교 석사학위논문; 2019 |
| 이소연; 부산대학교 석사학위논문; 2020 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230022571A (en) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102207995B1 (en) | Composition for Anti-microbial, Anti-inflammation, and Skin Hydration Property Comprising Fermented Extract of Momordica charantia as Active Ingredient | |
| EP2711014B1 (en) | Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis | |
| US10130670B2 (en) | Composition for treating or preventing inflammatory skin disease, comprising, as active ingredient, immature citrus fruit extract, or synephrine or salt thereof | |
| KR101977954B1 (en) | Compositions for Treating or Preventing Inflammatory Disease Comprising Extract of Hibiscus Syriacus | |
| US7511078B2 (en) | Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same | |
| KR102065185B1 (en) | Composition for Improving Skin Conditions with Improved Anti-Bacterial, Anti-inflammatory, Anti-wrinkling, and Skin Whitening Property | |
| KR20240004199A (en) | Antibacterial composition containing extract or fractions of Prunus pendula for. ascendens | |
| JP2007176814A (en) | Zeaxanthin derivative having inhibiting action on production of inflammatory cytokine, and food product preparation, cosmetics, and anti-inflammatory agent comprising same | |
| KR20220166642A (en) | Composition for treating atopic dermatitis or strengthening skin barrier or preventing aging, comprising extract of Forsythia nakaii (Uyeki) T.B.Lee | |
| KR20190064714A (en) | Anti-inflammatory agent containing backhousia citriodora extract | |
| KR101394550B1 (en) | Anti-bacterial or Anti-inflammatory Composition Comprising Extracts from Flower of Rosa hybrida as Active Ingredient | |
| KR101433823B1 (en) | External Composition for Skin Using an Extract or a Fraction of Padina arborescens | |
| KR101392808B1 (en) | Antibacterial compositions containing plant extracts or fractions | |
| KR20100089409A (en) | Cosmetic composition for acne improvement | |
| KR101986629B1 (en) | Composition for anti-pruritic comprising grape pruning stem extract as effective component | |
| KR102642293B1 (en) | Composition for preventing or treating skin diseases comprising wikstroemia ganpi | |
| CN107427434A (en) | Promote the composition comprising genistein or Epigallo-catechin gallate (EGCG) of cell rejuvenation for inducing | |
| KR20200080556A (en) | Composition for preventing or treating skin disease comprising extract of Spiraea prunifolia simpliciflora | |
| CN113350232B (en) | Cosmetic composition for protecting skin and relieving irritation containing mixed extract of herba Portulacae, folium Artemisiae Argyi and radix Rhodiolae as effective components | |
| KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
| KR101702621B1 (en) | Anti-inflammatory agent containing phlox subulata extract | |
| KR20190085748A (en) | Compositions for skin regeneration, skin soothing or wound healing comprising sericin, extracts of erect hedge parsley extract and extracts of mistletoe | |
| KR102239415B1 (en) | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain | |
| KR20230001597A (en) | Anti-Inflammaging Compositions Comprising Fermented Extract of Cannabis sativa Stem as Active Ingredient | |
| JP2009001514A (en) | Anethole derivative having inflammatory cytokine production-inhibiting action, and food preparation, cosmetic and antiinflammatory agent comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |